Diet and Parkinson's disease II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study

Neurology

Volumn 47, Issue 3, 1996, Pages 644-650

  Hellenbrand, W ^a   Boeing, H ^b   Robra, B P ^a   Seidler, A ^c   Vieregge, P ^d   Nischan, P ^c   Joerg, J ^e,i   Oertel, W H ^f,i   Schneider, E ^h,i   Ulm, G ^g,i  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e Barmen Hospital   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g Paracelsus Elena Hospital   (Germany)

^h Asklepios Klinik Harburg   (Germany)

ⁱ Medical Advisory Board   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BETA CAROTENE; COBALAMIN; DISACCHARIDE; FOLIC ACID; MONOSACCHARIDE; NICOTINIC ACID; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CARBOHYDRATE INTAKE; CASE CONTROL STUDY; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; FAT INTAKE; FEMALE; FOOD INTAKE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL REQUIREMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN INTAKE; VITAMIN INTAKE;

EID: 9544227379     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.3.644     Document Type: Article

References (45)

1. Hellenbrand W, Seidler A, Boeing H, et al. Diet and Parkinson's disease I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996;47:636-643.
2. Seidler A, Hellenbrand W, Robra BP, et al. Possible environmental, occupational and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996;46:1275-1284.
3. Hughes AJ, Daniel SE, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55: 181-184.
4. Jessen RJ. Statistical survey techniques. New York: John Wiley and Sons, 1978.
5. Bohlscheid-Thomas S, Hoting J, Boeing H, Wahrendorf J. Reproducibility and validity of food group intake of a food frequency questionnaire developed for the German part of the EPIC-project. Int J Epidemiol, in press.
6. Bohlscheid-Thomas S, Hoting J, Boeing H, Wahrendorf J. Reproducibility and validity of energy and macronutrient intake of a food frequency questionnaire developed for the German part of the EPIC-project. Int J Epidemiol, in press.
7. Boeing H, Bohlscheid-Thomas S, Voss S, Schneeweiss S, Wahrendorf J. The relative validity of vitamin intakes derived from a food frequency questionnaire compared to 24-hr-recalls and biological measurements: Results from the EPIC pilot study in Germany. Int J Epidemiol, in press.
8. Federal Institute for Consumer Health Protection, Germany. Bundeslebensmittelschlüssel (BLS), Version II.2, 1994.
9. Willett, W. Nutritional epidemiology. New York: Oxford University Press, 1990.
10. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1. The analysis of case-control studies. Lyon: IARC Scientific Publication No. 32, International Agency for Research on Cancer, 1982.
11. Schlesselman JJ. Case-control studies. Design, conduct, analysis. Oxford: Oxford University Press, 1982.
12. Gorell JM, Johnson CC, Rybicki BA, Booker P, Wulbrecht N, Sanders K. Nutrient intake in Parkinson's disease: a case-control study. Mov Disord 1994;9(Suppl 1):75.
13. Levi S, Cox M, Lugon M, et al. Increased energy expenditure in Parkinson's disease. BMJ 1990;301:1256-1257.
14. Berry EM, Growdon JH, Wurtman JJ, Caballero B, Wurtman RJ. A balanced carbohydrate: protein diet in the management of Parkinson's disease. Neurology 1991;41:1295-1297.
15. Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann Neurol 1992; 32:S82-S87.
16. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32: 804-812.
17. Olanow CW. A radical hypothesis for neuronal degeneration. Trends Neurosci 1993;16:439-444.
18. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
19. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
20. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate Superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989;53:692-697.
21. Marttila RJ, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in Parkinson's disease. J Neurol Sci 1988:86:321-331.
22. Dexter DT, Brooks DJ, Harding AE, et al. Nigrostriatal function in Vitamin E deficiency: clinical, experimental, and positron emission tomographic studies. Ann Neurol 1994;35: 298-303.
23. Grünewald RA. Ascorbic acid in the brain. Brain Res Rev 1993;18:123-132.
24. Tanner CM, Cohen JA, Summerville BC, Goetz CG, Vitamin use and Parkinson's disease [abstract]. Ann Neurol 1988;23: 182.
25. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 1992;Suppl 32: 128-132.
26. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
27. Yapa SCS. Detection of subclinical ascorbate deficiency in early Parkinson's disease. Public Health 1992;106:393-395.
28. Friedrich W. Handbuch der Vitamine. München: Urban u. Schwarzenberg, 1987.
29. Bender DA, Njagi ENM, Danielian PS. Tryptophan metabolism in vitamin B6-deficient mice. Br J Nutr 1990:63:27-36.
30. Bender DA. Effects of a dietary excess of leucine and of the addition of leucine and 2-oxo-isocaproate on the metabolism of tryptophan and niacin in isolated rat liver cells. Br J Nutr 1989;61:629-640.
31. Bender DA. Inhibition of tryptophan-niacin metabolism by dietary leucine and by leucine and 2-oxo-isocaproate in vitro. Adv Exp Med Biol 1991;294:501-504.
32. Hastings TG, Zigmond MJ. Identification of catechol-protein conjugates in neostriatal slices incubated with (3H)Dopamine: impact of ascorbic acid and glutathione. J Neurochem 1994; 63:1126-1132.
33. Suzuki T, Fujita S, Narimatsu S, et al. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. FASEB J 1992;6:771-776.
34. Fonne-Pfister R, Bargetzi MJ, Meyer UA. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufl, P450dl) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987;148:1144-1150.
35. Barbeau A, Roy M, Cloutier T, Plasse L, Paris S. Environmental and genetic factors in the etiology of Parkinson's disease. Adv Neurol 1986;45:299-306.
36. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-1377.
37. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-1018.
38. Jiménez-Jiménez FJ, Tabernero C, Mena MA, et al. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. J Neurochem 1991;57:81-87.
39. Birkmayer JGD, Birkmayer W. Stimulation of endogenous L-dopa biosynthesis - a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH). Acta Neurol Scand 1989;126:183-187.
40. Birkmayer W, Birkmayer JGD, Vrecko K, Paletta B. The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients. Adv Neurol 1990;53:545-549.
41. Birkmayer W, Birkmayer JGD, Vrecko C, Paletta B, Reschenhofer E, Ott E. Nicotinamide adenine nucleotide (NADH) as medication for Parkinson's disease. Experience with 415 Patients. New Trends Clin Neuropharmacol 1990;4:7-24.
42. Williams AC. Dopamine, dystonia, and the deficient cofactor. Lancet 1995;345:1130.
43. Williams A, Sturman S, Steventon G, Waring R. Metabolic biomarkers of Parkinson's disease. Acta Neurol Scand 1991; 84:Suppl 136:19-23.
44. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.
45. Sandyk R, Pardeshi R. Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient. Int J Neurosci 1990;52:225-232.